NCT04598542View on ClinicalTrials.gov

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Drug-Drug Interaction
Interventions
DRUG

Lorecivivint (LOR)

0.07 mg

DRUG

Triamcinolone acetonide (TA)

40 mg

Trial Locations (1)

33126

Research Site, Miami

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY

NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers | Biotech Hunter | Biotech Hunter